Reuters -- Sanofi-Aventis’ (SASY.PA) cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.
Reuters -- Sanofi-Aventis’ (SASY.PA) cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.
